Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Ryoga Hamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1670-4435; OpenAlex author ID A5027661140. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 5 papers · 2022: 4 papers · 2023: 4 papers · 2024: 1 paper · 2025: 4 papers · 2026: 4 papers

Papers 25

  1. Number of Liver Metastases Stratifies Prognosis in Synchronous Metastatic Pancreatic Cancer. Co-author DOI 10.1002/wjs.70666↗
  2. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. First author DOI 10.1007/s00595-026-03416-8↗
  3. Pancreatic ductal adenocarcinoma originating from focal pancreatic parenchymal atrophy demonstrated by transabdominal ultrasonography. Co-author DOI 10.1007/s12328-025-02202-2↗
  4. Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.21873/cdp.10600↗
  5. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… Co-author DOI 10.1007/s00595-025-03050-w↗
  6. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  7. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. Co-author DOI 10.1016/j.suronc.2024.102179↗
  8. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … Co-author DOI 10.1177/00031348241278016↗
  9. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.16968↗
  10. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  11. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348231204912↗
  12. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. Co-author DOI 10.21873/anticanres.16150↗
  13. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  14. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  15. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer durin… Co-author DOI 10.1007/s12032-021-01625-4↗
  16. Inhibition of lysosomal acid β-glucosidase induces cell apoptosis via impairing mitochondrial clearance in pancreatic cancer. Co-author DOI 10.1093/carcin/bgac060↗
  17. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Co-author DOI 10.1371/journal.pone.0267623↗
  18. Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer. Co-author DOI 10.1002/ags3.12447↗
  19. Practical significance of pancreatectomy with lymphadenectomy around the superior mesenteric artery for pancreatic cancer: comparison of prognosis after adjust… Co-author DOI 10.1007/s00423-021-02166-0↗
  20. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01964-2↗
  21. Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer. Co-author DOI 10.1111/cas.14921↗
  22. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Co-author DOI 10.1111/cas.15123↗
  23. Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. Co-author DOI 10.21873/anticanres.13952↗
  24. Combination of Distance from Superior Mesenteric Artery and Serum CA19-9 as a Novel Prediction of Local Recurrence in Patients With Pancreatic Cancer Following… Co-author DOI 10.21873/anticanres.13264↗
  25. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… Co-author DOI 10.21873/anticanres.13013↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 21 shared papers, 2021–2026 · strength 3.76
  2. Yoshihiro Shirai · 21 shared papers, 2018–2026 · strength 3.59
  3. Kenei Furukawa · 20 shared papers, 2018–2026 · strength 3.54
  4. Koichiro Haruki · 17 shared papers, 2018–2026 · strength 2.94
  5. Masashi Tsunematsu · 13 shared papers, 2022–2026 · strength 2.71
  6. Shinji Onda · 13 shared papers, 2021–2026 · strength 2.33
  7. Takeshi Gocho · 13 shared papers, 2018–2026 · strength 2.14
  8. Michinori Matsumoto · 9 shared papers, 2023–2026 · strength 1.91
  9. Kyohei Abe · 8 shared papers, 2022–2025 · strength 1.54
  10. Tadashi Uwagawa · 9 shared papers, 2021–2025 · strength 1.45
  11. Yoshiaki Tanji · 6 shared papers, 2023–2026 · strength 1.28
  12. Tomohiko Taniai · 8 shared papers, 2021–2026 · strength 1.27
  13. Mitsuru Yanagaki · 7 shared papers, 2021–2026 · strength 1.19
  14. Taro Sakamoto · 6 shared papers, 2019–2026 · strength 1.10
  15. Norimitsu Okui · 3 shared papers, 2025–2026 · strength 0.76
  16. Takashi Horiuchi · 6 shared papers, 2018–2022 · strength 0.71
  17. Hiroaki Shiba · 6 shared papers, 2018–2022 · strength 0.70
  18. Shuichi Fujioka · 4 shared papers, 2022–2025 · strength 0.70
  19. Hironori Shiozaki · 4 shared papers, 2021–2024 · strength 0.63
  20. Katsuhiko K. Yanaga · 5 shared papers, 2018–2022 · strength 0.57
  21. Yuki Fujiwara · 4 shared papers, 2018–2022 · strength 0.43
  22. Yosuke Igarashi · 2 shared papers, 2023–2025 · strength 0.39
  23. Shogo Sakata · 1 shared paper, 2026 · strength 0.29
  24. Satoshi Shiozawa · 1 shared paper, 2026 · strength 0.29
  25. Takashi Aida · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.